MOH Insider Sale: Ronna Romney Disposes of 700 Shares at $153.74 VWAP

Rhea-AI Filing Summary

Ronna Romney, a director of Molina Healthcare (MOH), filed a Form 4 reporting a sale of 700 shares of Molina Healthcare common stock on 08/06/2025 at a volume-weighted average selling price of $153.74 with individual sale prices reported in the range $153.43 to $154.32. The filing shows 17,131 shares are beneficially owned indirectly by the Ronna Romney Revocable Trust. The Form was filed by one reporting person and executed on behalf of Ms. Romney by Jeff D. Barlow under power of attorney on 08/08/2025.

The filing includes an explanatory note that the reported price is the VWAP for sales on the transaction date and offers to provide detailed per-price quantities to Commission staff on request. No derivative transactions are reported and the Form does not state a reason for the sale or explicitly indicate whether the sale was part of a Rule 10b5-1 plan.

Positive

• Transaction disclosed with specifics: sale date (08/06/2025), amount (700 shares) and VWAP ($153.74) including price range ($153.43–$154.32).
• Beneficial ownership disclosed: 17,131 shares held indirectly by the Ronna Romney Revocable Trust.
• No derivative activity reported: Table II is empty, indicating no options, warrants or other derivatives were involved in this filing.

Negative

• No reason for the sale provided: the Form does not state whether the disposition was for personal reasons, liquidity needs, or other purposes.
• No explicit 10b5-1 plan disclosure: the filing does not indicate whether the sale was executed pursuant to a Rule 10b5-1 trading plan.
• Relative size context missing: the filing does not state total prior direct holdings or percentage of holdings sold, limiting assessment of materiality.

Insights

Securities Analyst

TL;DR: A director sold a modest block of 700 MOH shares; disclosure is clear but offers no reason for the sale.

The Form 4 reports a single non-derivative disposition of 700 Molina Healthcare shares on 08/06/2025 at a VWAP of $153.74 with a disclosed price range of $153.43 to $154.32. Post-transaction beneficial ownership of 17,131 shares is shown as held indirectly by a revocable trust. From a trading-data perspective the filing is transparent: it provides transaction date, share count, VWAP and a commitment to disclose per-price quantities to the Commission on request. For investors, this is routine insider activity; the filing does not provide context such as whether the sale was pre-planned under a 10b5-1 arrangement or for personal reasons, which limits interpretive value.

Corporate Governance Expert

TL;DR: Disclosure meets Form 4 requirements but lacks explanatory context on intent or plan status.

The filing identifies the reporting person as a company director and clearly reports the disposition amount, execution date and VWAP range. It also discloses indirect beneficial ownership via a named revocable trust and includes an executed signature by a power of attorney. These elements satisfy key transparency expectations for insider reporting. The absence of an explicit statement about a trading plan or the reason for the sale means stakeholders do not receive governance context about whether the sale was routine portfolio management or otherwise, which is often relevant for board-level insiders.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ROMNEY RONNA

(Last) (First) (Middle)

2180 HARVARD STREET

SUITE 400

(Street)

SACRAMENTO CA 95815

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MOLINA HEALTHCARE, INC. [ MOH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/06/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/06/2025		S		700	D	$153.74(1)	17,131	I	Held by trust(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Price is the volume weighted average selling price of all sales by the Reporting Person on the transaction date within a one-dollar range. Actual prices ranged from $153.43 to $154.32. The Reporting Person hereby undertakes to provide upon request of the Commission staff full information regarding the number of shares sold at each separate price.

2. All shares held by Ronna Romney Revocable Trust.

Remarks:

	Jeff D. Barlow, by power of attorney for Ronna Romney.	08/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Ronna Romney report on the Form 4 for Molina Healthcare (MOH)?

The Form 4 reports a sale of 700 shares of Molina Healthcare common stock on 08/06/2025 at a VWAP of $153.74 with a disclosed price range of $153.43–$154.32.

How many Molina Healthcare (MOH) shares does the filing show Ms. Romney beneficially owning after the sale?

The filing shows 17,131 shares beneficially owned indirectly by the Ronna Romney Revocable Trust.

Does the Form 4 indicate the sale was part of a 10b5-1 trading plan?

The filing does not indicate whether the sale was made pursuant to a Rule 10b5-1 trading plan.

What price information is provided for the sale on the Form 4?

The price is reported as the volume-weighted average selling price (VWAP) of $153.74; individual sale prices ranged from $153.43 to $154.32 and the filer offers to provide per-price quantities to Commission staff on request.

Who signed the Form 4 and when was it signed?

The Form 4 was signed on behalf of Ronna Romney by Jeff D. Barlow under power of attorney on 08/08/2025.

What is Ms. Romney's relationship to Molina Healthcare noted on the filing?

The filing lists the reporting person as a Director of Molina Healthcare.